Pipeline DiversificationBHVN highlighted advances across the company's increasingly diversified pipeline portfolio, including in weight/muscle management, inflammation/autoimmune, neurological, and oncology.
Regulatory ConfidenceManagement sounded very confident in the SCA regulatory process, indicating its responses to the FDA’s questions were fairly easy and quick.
Research And DevelopmentBiohaven delivered another solid R&D Day with all programs moving forward as planned, and everything heard continues to support a positive investment thesis on the stock.